{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:55:14Z","timestamp":1771275314493,"version":"3.50.1"},"reference-count":81,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Takeda and Savient; and consultant fees from URL pharmaceuticals, Savient, Takeda, Ardea, Novartis and Allergan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.2217\/imt.13.10","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T15:41:19Z","timestamp":1362066079000},"page":"265-299","source":"Crossref","is-referenced-by-count":52,"title":["Harms of TNF Inhibitors in Rheumatic Diseases: A Focused Review of the Literature"],"prefix":"10.1080","volume":"5","author":[{"given":"Archana","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Medicine at School of Medicine, University of Alabama, Birmingham, AL, USA"}]},{"given":"Jasvinder A","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medicine at School of Medicine, University of Alabama, Birmingham, AL, USA"},{"name":"Division of Epidemiology at School of Public Health, University of Alabama, Birmingham, AL, USA"},{"name":"Medicine Service & Center for Surgical Medical Acute Care Research & Transitions, Birmingham VA Medical Center, Birmingham, AL, USA"},{"name":"Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA"}]}],"member":"301","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"e_1_3_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_3_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker194"},{"key":"e_1_3_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04621.x"},{"key":"e_1_3_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3149"},{"key":"e_1_3_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.829"},{"key":"e_1_3_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq325"},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.suppl_2.ii30"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.6.631"},{"key":"e_1_3_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102103"},{"key":"e_1_3_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21386"},{"key":"e_1_3_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_3_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22808"},{"key":"e_1_3_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep325"},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1692"},{"key":"e_1_3_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101675"},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem076"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22504"},{"key":"e_1_3_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318211106a"},{"key":"e_1_3_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"},{"key":"e_1_3_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg263"},{"key":"e_1_3_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel236"},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152769"},{"key":"e_1_3_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-52"},{"key":"e_1_3_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091025"},{"key":"e_1_3_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.734"},{"key":"e_1_3_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30310"},{"key":"e_1_3_3_3_28_1","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview.","volume":"2","author":"Singh JA","year":"2011","unstructured":"Singh JA , WellsGA, ChristensenR et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. 2 , CD008794 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_3_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091107"},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"e_1_3_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23050"},{"key":"e_1_3_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.146365"},{"key":"e_1_3_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.028597"},{"key":"e_1_3_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22600"},{"key":"e_1_3_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.035287"},{"issue":"8","key":"e_1_3_3_3_37_1","first-page":"992","volume":"171","author":"Dunlop H","year":"2004","unstructured":"Dunlop H . Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis. CMAJ171(8) , 992\u2013993 (2004).","journal-title":"CMAJ"},{"key":"e_1_3_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0336"},{"key":"e_1_3_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22768"},{"key":"e_1_3_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_3_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_3_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21137"},{"key":"e_1_3_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.137422"},{"key":"e_1_3_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1086\/383317"},{"key":"e_1_3_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60839-2"},{"key":"e_1_3_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089276"},{"key":"e_1_3_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_3_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125658"},{"key":"e_1_3_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1086\/598331"},{"key":"e_1_3_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1086\/421494"},{"key":"e_1_3_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep376"},{"key":"e_1_3_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3087"},{"issue":"4","key":"e_1_3_3_3_54_1","first-page":"689","article-title":"Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study.","volume":"34","author":"Den Broeder AA","year":"2007","unstructured":"Den Broeder AA , CreemersMC, FransenJ et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J. Rheumatol. 34(4) , 689\u2013695 (2007).","journal-title":"J. Rheumatol."},{"key":"e_1_3_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033993"},{"key":"e_1_3_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken026"},{"key":"e_1_3_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20129"},{"key":"e_1_3_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2046"},{"key":"e_1_3_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.20.2337"},{"key":"e_1_3_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj004"},{"key":"e_1_3_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.117762"},{"key":"e_1_3_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.085852"},{"key":"e_1_3_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033241"},{"key":"e_1_3_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22579"},{"key":"e_1_3_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20311"},{"key":"e_1_3_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.07.006"},{"key":"e_1_3_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030528"},{"key":"e_1_3_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831050-00013"},{"key":"e_1_3_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.02.016"},{"key":"e_1_3_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.2165\/11590200-000000000-00000"},{"key":"e_1_3_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.02.025"},{"key":"e_1_3_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.09.039"},{"key":"e_1_3_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23281"},{"key":"e_1_3_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-006-0215-3"},{"key":"e_1_3_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem212"},{"issue":"10","key":"e_1_3_3_3_76_1","first-page":"1958","article-title":"Arrhythmic risk during acute infusion of infliximab. a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis.","volume":"35","author":"Lazzerini PE","year":"2008","unstructured":"Lazzerini PE , AcampaM, HammoudM et al. Arrhythmic risk during acute infusion of infliximab. a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J. Rheumatol. 35(10) , 1958\u20131965 (2008).","journal-title":"J. Rheumatol."},{"key":"e_1_3_3_4_2_1","unstructured":"US FDA. Information for healthcare professionals: Cimzia (certolizumab pegol) Enbrel (etanercept) Humira (adalimumab) and Remicade (infliximab) (2008). www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124185.htm"},{"key":"e_1_3_3_4_3_1","unstructured":"US FDA. Etanercept: drug label (2009). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/103795s5415lbl.pdf"},{"key":"e_1_3_3_4_4_1","unstructured":"US FDA. FDA drug safety communication: Drug labels for the TNF-\u03b1 blockers now include warnings about infection with Legionella and Listeria bacteria (2011). www.fda.gov\/Drugs\/DrugSafety\/ucm270849.htm"},{"key":"e_1_3_3_4_5_1","unstructured":"US FDA. Infliximab: drug label (2011). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103772s5295lbl.pdf"},{"key":"e_1_3_3_4_6_1","unstructured":"US FDA. Adalimumab: drug label (2011). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/125057s0276lbl.pdf"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.13.10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T12:25:24Z","timestamp":1715948724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.13.10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.2217\/imt.13.10"],"URL":"https:\/\/doi.org\/10.2217\/imt.13.10","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}